These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17415469)

  • 1. Comparative analysis of efficiency and specificity of various sorbents for apheresis of low-density lipoproteins.
    Afanas'eva OI; Altynova EV; Boldyrev AG; Sokolov AA; Adamova IY; Pokrovskii SN
    Bull Exp Biol Med; 2006 Nov; 142(5):587-90. PubMed ID: 17415469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL-apheresis as long-term treatment in severe hyperlipidemia using differing methods.
    Bambauer R; Schiel R; Latza R; Schneidewind JM
    ASAIO J; 1999; 45(5):408-12. PubMed ID: 10503616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
    Otto C; Berster J; Otto B; Parhofer KG
    J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosorptive apheresis of LDL.
    Borberg H; Gaczkowski A; Oette K; Stoffel W
    Prog Clin Biol Res; 1990; 337():163-7. PubMed ID: 2191310
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
    Bosch T; Lennertz A; Schenzle D; Dräger J;
    J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
    Gordon BR; Saal SD
    J Clin Apher; 1996; 11(3):128-31. PubMed ID: 8915816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein-apheresis in two patients with extremely elevated lipoprotein (a) levels.
    Bambauer R; Schiel R; Klinkmann J; Latza R
    J Clin Apher; 1996; 11(2):78-80. PubMed ID: 8844436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.
    Schmaldienst S; Banyai S; Stulnig TM; Heinz G; Jansen M; Hörl WH; Derfler K
    Atherosclerosis; 2000 Aug; 151(2):493-9. PubMed ID: 10924726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques.
    Kopprasch S; Graessler J; Bornstein SR; Schwarz PE; Tselmin S; Frind A; Poberschin I; Julius U
    Atheroscler Suppl; 2009 Dec; 10(5):34-8. PubMed ID: 20129371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of different lipoprotein apheresis methods on serum protein levels.
    Julius U; Siegert G; Kostka H; Schatz U; Hohenstein B
    Atheroscler Suppl; 2015 May; 18():95-102. PubMed ID: 25936311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study.
    Wendler T; Schilling R; Lennertz A; Sodemann K; Kleophas W; Messner H; Riechers G; Wagner J; Keller C; Bosch T
    J Clin Apher; 2003; 18(4):157-66. PubMed ID: 14699591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions.
    Bosch T; Gahr S; Belschner U; Schaefer C; Lennertz A; Rammo J;
    Ther Apher Dial; 2006 Jun; 10(3):210-8. PubMed ID: 16817783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Schneidewind JM; Latza R
    ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein apheresis: principles and indications.
    Winters JL
    Semin Dial; 2012; 25(2):145-51. PubMed ID: 22277063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis.
    Hequet O; Le QH; Rigal D; Mekhloufi F; Jaeger S; Sassolas A; Groisne L; Moulin P
    Transfus Apher Sci; 2010 Feb; 42(1):3-10. PubMed ID: 19932056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why an apheresis center should offer more than one lipoprotein apheresis method.
    Julius U; Fischer S; Schatz U; Passauer J; Bornstein S
    Ther Apher Dial; 2013 Apr; 17(2):179-84. PubMed ID: 23551674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid reductions by low-density lipoprotein apheresis: a comparison of three systems.
    Jovin IS; Taborski U; Stehr A; Müller-Berghaus G
    Metabolism; 2000 Nov; 49(11):1431-3. PubMed ID: 11092506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-apheresis in two patients with extremely elevated lipoprotein (a) levels.
    Bambauer R; Schiel R; Keller HE; Latza R
    Int J Artif Organs; 1995 May; 18(5):286-90. PubMed ID: 8567105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of a heparin-citrate anticoagulation for LDL-apheresis in two primary apheresis systems.
    Handschel D; Etienne Janssens M; Gericke M; De Reys S; Borberg H
    J Clin Apher; 2017 Oct; 32(5):319-328. PubMed ID: 27676234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperlipidemia with a modified low density lipoprotein apheresis system with dextran sulfate.
    Zhao YH; Zou YG; Sun QJ; Xi D; Xing CY
    Ther Apher Dial; 2007 Aug; 11(4):249-54. PubMed ID: 17661829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.